Traynor Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-4,813
| Closed | -$298K | – | 181 |
|
|
2022
Q1 | $298K | Sell |
4,813
-1,064
| -18% | -$65.9K | 0.04% | 136 |
|
|
2021
Q4 | $476K | Buy |
5,877
+858
| +17% | +$69.5K | 0.06% | 129 |
|
|
2021
Q3 | $476K | Buy |
5,019
+690
| +16% | +$65.4K | 0.07% | 121 |
|
|
2021
Q2 | $432K | Buy |
4,329
+212
| +5% | +$21.2K | 0.06% | 122 |
|
|
2021
Q1 | $344K | Buy |
4,117
+570
| +16% | +$47.6K | 0.06% | 121 |
|
|
2020
Q4 | $306K | Sell |
3,547
-630
| -15% | -$54.4K | 0.05% | 118 |
|
|
2020
Q3 | $295K | Buy |
4,177
+123
| +3% | +$8.69K | 0.07% | 112 |
|
|
2020
Q2 | $294K | Buy |
+4,054
| New | +$294K | 0.07% | 116 |
|
|
2018
Q4 | – | Sell |
-3,969
| Closed | -$276K | – | 162 |
|
|
2018
Q3 | $276K | Sell |
3,969
-27
| -0.7% | -$1.88K | 0.09% | 140 |
|
|
2018
Q2 | $232K | Sell |
3,996
-280
| -7% | -$16.3K | 0.08% | 152 |
|
|
2018
Q1 | $235K | Buy |
4,276
+67
| +2% | +$3.68K | 0.1% | 146 |
|
|
2017
Q4 | $235K | Buy |
4,209
+497
| +13% | +$27.7K | 0.1% | 144 |
|
|
2017
Q3 | $223K | Buy |
+3,712
| New | +$223K | 0.11% | 137 |
|
|
2016
Q4 | – | Sell |
-6,511
| Closed | -$268K | – | 132 |
|
|
2016
Q3 | $268K | Sell |
6,511
-1,579
| -20% | -$65K | 0.19% | 99 |
|
|
2016
Q2 | $320K | Sell |
8,090
-3,005
| -27% | -$119K | 0.25% | 88 |
|
|
2016
Q1 | $453K | Buy |
11,095
+5,426
| +96% | +$222K | 0.36% | 60 |
|
|
2015
Q4 | $405K | Sell |
5,669
-2,566
| -31% | -$183K | 0.29% | 75 |
|
|
2015
Q3 | $479K | Buy |
8,235
+1,550
| +23% | +$90.2K | 0.41% | 53 |
|
|
2015
Q2 | $604K | Buy |
6,685
+645
| +11% | +$58.3K | 0.5% | 43 |
|
|
2015
Q1 | $478K | Buy |
6,040
+2,170
| +56% | +$172K | 0.46% | 47 |
|
|
2014
Q4 | $242K | Buy |
+3,870
| New | +$242K | 0.28% | 85 |
|